Skip to Content

Tradjenta Approval History

  • FDA approved: Yes (First approved May 2nd, 2011)
  • Brand name: Tradjenta
  • Generic name: linagliptin
  • Dosage form: Tablets
  • Company: Boehringer Ingelheim Pharmaceuticals Inc.
  • Treatment for: Diabetes, Type 2

Tradjenta (linagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Development History and FDA Approval Process for Tradjenta

Aug 17, 2012Approval FDA approves updated prescribing information for Tradjenta (linagliptin) tablets for add-on therapy to insulin in adults with type 2 diabetes
May  2, 2011Approval FDA Approves Tradjenta for Type 2 Diabetes

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.